Mixed adenoneuroendocrine carcinomas of stomach and ampulla of vater after curative-intent resection: a single center cases series

Sishu Yang
West China Hospital of Sichuan University

Jiong Lu
West China Hospital of Sichuan University

Yulong Cai
West China Hospital of Sichuan University

Bei Li
West China Hospital of Sichuan University

Xianze Xiong (✉ xianzexiong123@163.com)
West China Hospital of Sichuan University

Research Article

Keywords: Mixed adenoneuroendocrine carcinomas, prognosis, digestive system neoplasms

DOI: https://doi.org/10.21203/rs.3.rs-534942/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

Mixed adenoneuroendocrine carcinoma is a rare clinical manifestation, especially in the gastric and ampullary. The purpose of this study was to investigate the clinicopathological features and prognosis of mixed adenoneuroendocrine carcinoma in the gastric and ampullary and summarize related treatment suggestions.

Methods

In all, 32 cases of mixed adenoneuroendocrine carcinoma in the gastric and ampullary that were diagnosed from resected specimens were analyzed from 2009–2015. The corresponding demographic, clinicopathological and survival data were retrospectively reviewed.

Results

The 1-year, 3-year and 5-year survival rates were 78.1%, 28.1% and 9.4%, respectively, and the median overall survival was 28.0 months. In all, 75.0% (24/32) had lymph node metastasis at the time of initial diagnosis. A multivariate analysis revealed that TNM stage(HR6.444 95%CI 1.477–28.121 P = 0.013), lymph nodes metastasis (HR10.617 95%CI 1.409–79.997 P = 0.022), vascular invasion (HR 5.855 95%CI 1.719–19.940 P = 0.005),grade of the adenocarcinoma component (HR 3.876 95% CI 1.451–10.357 P = 0.007) and CD56 positivity (HR 0.265 95% CI 0.100-0.705 P = 0.008)were independent predictors of overall survival.

Conclusions

Mixed adenoneuroendocrine carcinoma is an aggressive clinical entity with a poor prognosis. Taking both the neuroendocrine component and the adenocarcinoma component into consideration of optimal treatment is strongly recommended.

Background

According to the recent WHO classification from 2010, mixed adenoneuroendocrine carcinomas (MANEC) are composed of both malignant neuroendocrine and exocrine components, and each of them must exceed 30% of the entire tumor cell population(1). Synaptophysin(Syn), chromogranin(CgA) and CD56 are commonly used neuroendocrine makers, two of which must be positive for a diagnosis of MANEC(2, 3). MANEC is clinically rare, and its morphology is recognizable as both gland-forming epithelial and neuroendocrine neoplasms(4). MANECs have been reported in the colon, rectum, esophagus, stomach, and pancreas, among other sites. Although most of them are case reports(5–8), a few studies of MANEC
cases in the gastric and ampullary on a much larger scale have been published, the clinicopathological features and prognosis of patients with MANEC in the gastric and ampullary are still unclear, which may account for the deficiency in optimal treatments for MANECs. In our study, the data of 32 MANEC patients who were treated at West China hospital between 2009–2015 were retrospectively analyzed. In this study, we analyzed the clinicopathological features and prognosis of patients with MANEC in the gastric and ampullary and summarized related treatment suggestions according to other recently published literatures.

Methods

Study subjects

This is a retrospective study. From January 2009 to December 2015, there were totally 32 patients who were diagnosed as MANEC in WestChina hospital. All the cases underwent curative-intent resections and were diagnosed by pathology; the pathological diagnosis was supported by multiple histologic examinations including hematoxylin and eosin staining and immunohistochemical staining (Figure.1). Tumors that were not composed of adenocarcinoma or a poorly differentiated neuroendocrine carcinoma were excluded. If either the exocrine or neuroendocrine components did not exceed 30% of the entire neoplasm, cases were also excluded.

Clinicopathological data

All the data obtained from the patients was retrospectively reviewed and included age, gender, symptoms, blood type, tumor location, levels of serum alpha fetoprotein (AFP), carbohydrate antigen 19-9 (CA19-9) and carcino embryonic antigen (CEA), ultrasonography, computed tomography, magnetic resonance image and treatments. All the resected specimens were reviewed pathologically and were assessed for tumor size, depth of invasion, pathological classification, histological differentiation, lymph node status, presence of lymphatic and perineural invasion, cell types of neuroendocrine carcinoma, vascular invasion, Ki-67 index and immunohistochemical staining. The margins were examined for the presence of residual tumor, which was described by the residual tumor classification, as follows: R0, no residual tumor and resection margin was >0 mm; R1, microscopic residual tumor; R2, macroscopic residual tumor. Tumors were staged according to the American Joint Committee on Cancer (AJCC) 7th TNM staging system (9).

Follow-up

All the patients received clinical and radiographic follow-up every 2-3 months the first year after the surgery and then 3-6 months annually thereafter. The patients who were at high risk for recurrence received chemotherapy. Patients were followed-up for survival until death or the deadline of this study, which was December 31st, 2017.

Statistical analysis
Overall survival (OS) was calculated from the time of surgical resection to the time of death. Disease-free survival (DFS) was estimated from the time of surgical resection until the time of relapse confirmed by biopsy or radiologic imaging. Survival curves were generated by the Kaplan-Meier method, and the log-rank test was performed to evaluate the survival difference. All predictors that were statistically correlated with survival in the univariable analysis were included in a multivariable analysis using the Cox proportional regression model. When the P value was less than 0.05, the difference was considered statistically significant. SPSS 24.0 statistics software was used for data analysis.

Results

Clinical and pathological characteristics

The detailed characteristics are summarized in Table 1. This study included 32 cases of MANEC, including 25 cases in the stomach and 7 cases in the ampulla of Vater. The median age at diagnosis was 59.5 years (range, 48 to 74 years). In all, 78.1% patients were diagnosed with stage III/IV disease, and 75.0% had lymph node metastasis at the time of initial diagnosis. All the patients underwent radical resection with or without neoadjuvant chemotherapy. All of them were R0 resections. Eleven patients (34.4%) received chemotherapy after surgery, all of whom received platinum drugs, including EP (etoposide+cisplatin) (54.5%, 6/11) and SP (gemcitabine+cisplatin) (45.5%, 5/11). The pathological grade of the neuroendocrine component in all cases was G3. The pathological pattern of the adenocarcinoma component was well differentiated (9.3%), moderately differentiated (37.5%), poorly differentiated (31.3%) and signet ring cell/mucin (21.9%). Immunohistochemical staining was positive for chromogranin (81.3%), synaptophysin (96.9%) and CD56 (56.3%), and the positivity rates for PCK, EMA, and CK7 were 56.3%, 34.4% and 25.0%, respectively.

Postoperative recurrence

The deadline for follow-up was December 2017. All 32 patients were followed-up with a median follow-up time of 38.0 months (range, 6.0-68.0 months). During the follow-up, 16 (50.0%) patients experienced recurrence. Moreover, 43.8% (7/16) of patients had multiple recurrences, most of which occurred in the retroperitoneal lymph nodes (75.0%, 12/16). The median DFS was 22.0 months. In the univariate analysis, tumor size $\leq$ 3cm (P = 0.036); lymphatic invasion (P=0.027) (Figure.2); grade of the adenocarcinoma component (P = 0.000); CD56 (+)(P = 0.017); lymph nodes metastasis (P= 0.013)and vascular invasion(P = 0.006) (Figure.3)were defined as predictors of DFS (Table 2). The factor that was statistically significant in the univariate analysis was included in the Cox model. In the multivariate analysis, lymph nodes metastasis (HR8.380 95%CI 1.096-64.094 P=0.041) , vascular invasion (HR 9.923 95%CI 1.298-75.864 P=0.027), grade of the adenocarcinoma component (HR 6.331 95% CI 2.046-19.587 P=0.001),and CD56 positivity (HR 0.318 95% CI 0.112-0.906 P=0.032) were independent prognostic predictor of DFS (Table 2).

Overall survival
The median overall survival was 28.0 months. The 1-year, 3-year and 5-year survival rates were 78.1%, 28.1% and 9.4%, respectively. In the univariate analysis, tumor size <3cm (P=0.001), lymphatic invasion (P=0.018), vascular invasion (P=0.006), lymph node metastasis (P=0.004), TNM stage (P=0.004), grade of the adenocarcinoma component (P=0.003)(Figure.4) and CD56 positivity (P=0.006)(Figure.5) were associated with the outcome (Table 3). In the multivariate analysis, TNM stage (HR 6.444 95% CI 1.477-28.121 P=0.013), lymph node metastasis (HR 10.617 95% CI 1.409-79.997 P=0.022), vascular invasion (HR 5.855 95% CI 1.719-19.940 P=0.005), grade of the adenocarcinoma component (HR 3.876 95% CI 1.451-10.357 P=0.007) and CD56 positivity (HR 0.265 95% CI 0.100-0.705 P=0.008) were independent predictors of overall survival (Table 3).

Discussion

MANEC is clinically rare since only when the exocrine and neuroendocrine components each exceed 30% can the tumor be considered as MANEC. Gastric and ampullary MANEC are highly exceptional entities(10–12). To the best of our knowledge, this research is the largest case series of MANEC in the gastric and ampullary.

Three commonly used neuroendocrine markers, Syn (96.9%), CgA (81.3%) and CD56 (56.3%), were all observed in our study. This result is similar to that of the study by Brathwaite, S. et al. in that Syn and CgA were expressed in 97% and 82% of cases, respectively(13). A previous report indicated that several markers, including CK7 and CK20, detected by immunohistochemical staining did not reveal any correlation with prognosis in MANECs(14). However, regarding hematopoietic stem cell markers, immunoreactivity for CD117 has already been considered an indicator of malignancy in pancreatic neuroendocrine carcinomas(15–18). In our study, we found that although CD56 was not as sensitive as CgA (81.3%) and Syn (96.9%), CD56 demonstrated a strong association with overall survival. CD56 is an important marker of neuroendocrine tumors and is also a glycoprotein of the immunoglobulin (Ig) superfamily expressed on natural kill (NK) cells, NK-T cells, and in vitro-expanded cytokineinduced cells(19). It had been shown that CD56+ cells exhibited cytotoxic effect against tumor targets(20). In our study, the OS of the CD56-positive group was much longer than that of the CD56-negative group ( 30.0 months versus 12.0 months) (P = 0.006). In the multivariate analysis, CD56 positivity (HR 0.265 95% CI 0.100,0.705 P = 0.008) was an independent prognostic predictor of OS. This may be related to the cytotoxic effect of CD56+ cells. However, CD56 was also expressed in a subset of biliary epithelial cells, especially in intrahepatic small bile ducts, and thus it might not be the best marker of neuroendocrine tumors in the biliary duct(21).

In this study, more than half of the patients presented with perineral invasion(13/32, 61.9%) or vascular invasion(13/32, 61.9%), which is a little lower than Wantanabe’s and La Rosa’s results (14, 22). In our study, vascular invasion (HR 5.855 95% CI 1.719–19.940 P = 0.005) was one of the independent predict factors on overall survival, which was consistent with La Rosa’s conclusion that vascular invasion had a negative effect on the prognosis(14). There were 84.4% of patients with the presence of the lymphatic invasion and it was a predict factor of bad outcome in univariate analysis (P = 0.018). which was
disagreement with the La Rosa’s result that the patients with the presence of lymphoid infiltrate had a better prognosis(14). But both of two analysis had a limited case samples of MANECs and were lost in multivariate analysis. Hence, further studies are needed on impact of lymphatic invasion.

The optimal treatment of MANEC is still controversial. Most published studies have indicated that the treatment should be based on the most aggressive histologic component(4, 10, 23), but which histologic component is the most aggressive? Some research has focused on this question. Chen et al. reported that the pure neuroendocrine component accounts for a large proportion (6/9) of lymph node metastasis in MANEC patients, and patients who have died had a predominantly neuroendocrine component in the primary tumor or in metastatic lymph nodes(24). This finding was in agreement with that of the study by Harada, K et al(25). They found that at the surface of the tumor, the adenocarcinoma components were in the highest flight. Neuroendocrine components are involved in most stromal and vascular invasion and LN metastasis. Moreover, neuroendocrine components showed higher proliferative activity than adenocarcinoma components(25, 26), which suggested that the neuroendocrine component was more aggressive and defined the prognosis of MANEC(27). However, in our study, we excluded all the patients with neuroendocrine tumors (G1/G2) according to the definition of MANEC by WHO(1), and we found that patients with well/moderately differentiated adenocarcinoma had a better prognosis. In the multivariate analysis, the grade of the adenocarcinoma component (HR3.876 95%CI 1.451–10.357 P = 0.007) was an independent predictor of overall survival, which was agreed with the conclusion of Nie's research(11). Hence, we suggested that the optimal treatment of MANEC should take both the neuroendocrine component and the adenocarcinoma component into consideration.

Several limitations of our study should be noted. Our data were retrospectively collected from a single medical center, which may carry an inherent risk of bias. The small sample size in this study also limited our ability to conduct further analyses. Despite these limitations, this study reflected the actual clinical features and prognostic factors of MANEC of the gastric and ampullary.

Conclusions

Overall, MANEC is a highly aggressive clinical entity with a poor prognosis. CD56 negativity may reveal a high risk for recurrence. Tumor size, lymph node metastasis and grade of the adenocarcinoma component were independent predictors of overall survival, hence, the grade of the adenocarcinoma component should be taken into consideration of the treatments as same as the neuroendocrine component. Radical resection of the tumor with aggressive multidisciplinary cancer management may improve the prognosis.

Abbreviations

MANEC
mixed adenoneuroendocrine carcinoma
Syn
Declarations

Ethics approval and consent to participate

All methods were performed in accordance with the Declaration of Helsinki. The present study was approved by the Institutional Ethical Board of West China hospital, Sichuan University. The requirement for informed consent was waived by the Institutional Ethical Board of West China hospital, Sichuan University due to the retrospective nature of the study.

Consent for publication

Not applicable.

Availability of data and materials

The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

None.

Authors' contributions


SS Yang and J Lu analyzed the data and wrote the manuscript; YL Cai and B Li helped with data analysis; XZ Xiong designed and supervised the writing of the manuscript; all authors approved the final manuscript as submitted.

Acknowledgements

None

References

1. Rindi GA, R.; Bosman, F.T.; Capella, C.; Kilmstra, D.S.; Kloppel, G.; Komminoth, P.; Solcia, E. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In WHO Classification of Tumours of the Digestive System. 2010;4th ed:13–4.

2. Rindi G, Bordi C, La Rosa S, Solcia E, Delle Fave G, Gruppo Italiano Patologi Apparato D, et al. Gastroenteropancreatic (neuro)endocrine neoplasms: the histology report. Dig Liver Dis. 2011;43 Suppl 4:S356-60.

3. Komminoth PC, C.; Klimstra, DS.; Klöppel, G.; Solcia, E.; Rindi, G. Neuroendocrine neoplasms of the appendix. WHO classification of tumours of the digestive system 4th ed. 2010.

4. La Rosa S, Marando A, Sessa F, Capella C. Mixed Adenoneuroendocrine Carcinomas (MANECs) of the Gastrointestinal Tract: An Update. Cancers (Basel). 2012;4(1):11-30.

5. Cherbanyak F, Gassend JL, Dimitrief M, Andrejevic-Blant S, Martinet O, Pezzetta E. A Rare Type of Colorectal Cancer: Mixed Adeno-Neuroendocrine Carcinoma (MANEC). Chirurgia (Bucur). 2017;112(2):152-6.

6. Juanmartinena JF, Fernandez-Urien I, Cordoba A, Miranda C, Borda A. Mixed adenoneuroendocrine carcinoma (MANEC) of the gastroesophageal junction: a case report and review of the literature. Rev Esp Enferm Dig. 2017;109(2):160-2.

7. Kheiri B, Osman M, Congdon D, Bachuwa G. A rare case of gastric mixed adenoneuroendocrine carcinoma (MANEC) with gastric Helicobacter pylori-negative mucosa-associated lymphoid tissue (MALT) lymphoma. BMJ Case Rep. 2017;2017.

8. Steel CJ, Hostetler V, Dunn D. A case of hyperfunctioning pancreatic mixed adenoneuroendocrine carcinoma (MANEC) arising from ectopic pancreatic tissue in the liver. Radiol Case Rep. 2014;9(4):1011.

9. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-4.

10. Duzkoylu Y, Aras O, Bostanci EB, Keklik Temucin T, Ulas M. Mixed Adeno-Neuroendocrine Carcinoma; Case Series of Ten Patients with Review of the Literature. Balkan Med J. 2018;35(3):263-7.

11. Nie L, Li M, He X, Feng A, Wu H, Fan X. Gastric mixed adenoneuroendocrine carcinoma: correlation of histologic characteristics with prognosis. Ann Diagn Pathol. 2016;25:48-53.
12. Mahansaria SS, Agrawal N, Arora A, Bihari C, Appukuttan M, Chattopadhyay TK. Ampullary Mixed Adenoneuroendocrine Carcinoma: Surprise Histology, Familiar Management. Int J Surg Pathol. 2017;25(7):585-91.

13. Brathwaite S, Rock J, Yearsley MM, Bekaii-Saab T, Wei L, Frankel WL, et al. Mixed Adenoneuroendocrine Carcinoma: An Aggressive Clinical Entity. Ann Surg Oncol. 2016;23(7):2281-6.

14. La Rosa S, Marando A, Furlan D, Sahnane N, Capella C. Colorectal Poorly Differentiated Neuroendocrine Carcinomas and Mixed Adenoneuroendocrine Carcinomas: Insights Into the Diagnostic Immunophenotype, Assessment of Methylation Profile, and Search for Prognostic Markers. Am J Surg Pathol. 2012;36(4):601-11.

15. Erler BS, Presby MM, Finch M, Hodges A, Horowitz K, Topilow AA, et al. CD117, Ki-67, and p53 predict survival in neuroendocrine carcinomas, but not within the subgroup of small cell lung carcinoma. Tumour Biol. 2011;32(1):107-11.

16. Kimiloglu Sahan E, Erdogan N, Ulusoy I, Samet E, Akyildiz Igdem A, Gonullu D. P53, Ki-67, CD117 expression in gastrointestinal and pancreatic neuroendocrine tumours and evaluation of their correlation with clinicopathological and prognostic parameters. Turk J Gastroenterol. 2015;26(2):104-11.

17. Yang DT, Holden JA, Florell SR. CD117, CK20, TTF-1, and DNA topoisomerase II-alpha antigen expression in small cell tumors. J Cutan Pathol. 2004;31(3):254-61.

18. Zhang L, Smyrk TC, Oliveira AM, Lohse CM, Zhang S, Johnson MR, et al. KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers. Am J Surg Pathol. 2009;33(10):1562-9.

19. Walmod PS, Kolkova K, Berezin V, Bock E. Zippers make signals: NCAM-mediated molecular interactions and signal transduction. Neurochem Res. 2004;29(11):2015-35.

20. Franceschetti M, Pievani A, Borleri G, Vago L, Fleischhauer K, Golay J, et al. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol. 2009;37(5):616-28 e2.

21. Kozaka K, Sasaki M, Fujii T, Harada K, Zen Y, Sato Y, et al. A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: 'bile ductular carcinoma'. Histopathology. 2007;51(3):390-400.

22. Watanabe J, Suwa Y, Ota M, Ishibe A, Masui H, Nagahori K, et al. Clinicopathological and Prognostic Evaluations of Mixed Adenoneuroendocrine Carcinoma of the Colon and Rectum: A Case-Matched Study. Dis Colon Rectum. 2016;59(12):1160-7.

23. Acosta AM, Wiley EL. Primary Biliary Mixed Adenoneuroendocrine Carcinoma (MANEC): A Short Review. Arch Pathol Lab Med. 2016;140(10):1157-62.

24. Chen H, Shu M, Chen S, Xue L, Lin Y. Clinicopathological features and lymph node metastatic patterns of gastric mixed adenoneuroendocrine carcinoma. Histol Histopathol. 2019;34(4):373-9.

25. Harada K, Sato Y, Ikeda H, Maylee H, Igarashi S, Okamura A, et al. Clinicopathologic study of mixed adenoneuroendocrine carcinomas of hepatobiliary organs. Virchows Arch. 2012;460(3):281-9.
26. Onishi I, Kitagawa H, Harada K, Maruzen S, Sakai S, Makino I, et al. Intraductal papillary neoplasm of the bile duct accompanying biliary mixed adenoneuroendocrine carcinoma. World J Gastroenterol. 2013;19(20):3161-4.

27. Li Y, Yau A, Schaeffer D, Magliocco A, Gui X, Urbanski S, et al. Colorectal glandular-neuroendocrine mixed tumor: pathologic spectrum and clinical implications. Am J Surg Pathol. 2011;35(3):413-25.

Tables

Table 1 The clinical and pathological characteristics of MANEC in the gastric and ampullary. MANEC Mixed adenoneuroendocrine carcinomas, *AJCC TNM staging system of tumors (7th edition, 2010)
| Variables                                      | MANEC (n=32) |
|-----------------------------------------------|--------------|
| Age, years, median (range)                    | 59.5 (48-74) |
| Sex, male/female, n                          | 26/6         |
| AFP, ng/ml, median (range)                    | 3.23 (1.04-64.65) |
| AFP >20 ng/ml, n (%)                          | 2 (6.2%)     |
| CA19-9, U/ml, median (range)                  | 12.82 (0.91-866.8) |
| CA19-9 > 40 U/ml, n (%)                       | 5 (15.6%)    |
| CEA, ng/ml, median (range)                    | 3.12 (0.93-86.67) |
| CEA >8 ng/ml, n (%)                           | 5 (15.6%)    |
| Tumor location, n                             |              |
| Ampulla of Vater                              | 7            |
| Stomach                                       | 25           |
| Tumor size <3 cm/>3 cm                        | 14/18        |
| T, n (%)                                      |              |
| T1                                            | 1 (3.1%)     |
| T2                                            | 6 (18.8%)    |
| T3                                            | 16 (50.0%)   |
| T4                                            | 9 (28.1%)    |
| Lymph node metastasis, n (%)                  | 24 (75.0%)   |
| TNM stage*, n (%)                             |              |
| I                                             | 2 (15.6%)    |
| II                                            | 5 (15.6%)    |
| III                                           | 24 (65.7%)   |
| IV                                            | 1 (3.1%)     |
| Ki67 median (range)                           | 50.0% (10.0%-90.0%) |
| Cell type of NEC, n (%)                       |              |
| Large cell                                    | 11 (34.4%)   |
| Mixed cell                                    | 14 (43.8%)   |
| Small cell                                    | 7 (21.8%)    |
|                          |        |
|--------------------------|--------|
| Lymphatic invasion Yes/No| 27/5   |
| Angioinvasion Yes/No     | 18/14  |
| Perineural invasion Yes/No| 20/12  |
| Differentiation of adenocarcinoma, n (%) | |
| Well differentiation     | 3 (9.3%)|
| Moderate differentiation | 12 (37.5%)|
| Poor differentiation     | 10 (31.3%)|
| Signet ring cell/Mucin   | 7 (21.9%)|
| Syn (+), n (%)           | 31 (96.9%)|
| CgA (+), n (%)           | 26 (81.3%)|
| CD56 (+), n (%)          | 18 (56.3%)|
| EMA(+) n (%)             | 11 (34.4%)|
| PCK(+) n (%)             | 18 (56.3%)|
| CK7(+) n (%)             | 8 (25.0%)|
| Chemotherapy, n (%)      | 11 (34.4%)|

**Table 2** Univariate and multivariate analyses of prognostic factors that influence recurrence of MANEC in the gastric and ampullary. MANEC Mixed adenoneuroendocrine carcinomas, *AJCC TNM staging system of tumors (7th edition, 2010)*
| Variables                  | Univariate analysis | Multivariate analysis |
|----------------------------|---------------------|-----------------------|
|                            | No. of patients (%) | MDFS (months) | P value | Hazard ratio (95% CI) | P value |
| Age (years)                |                     |                     |         |                       |         |
| <60                        | 16                  | 20.0               | 0.402   |                       |         |
| ≥60                        | 16                  | -                  |         |                       |         |
| Sex                        |                     |                     |         |                       |         |
| male                       | 26                  | -                  | 0.272   |                       |         |
| female                     | 6                   | 15.0               |         |                       |         |
| Tumor location             |                     |                     |         |                       |         |
| Stomach                    | 25                  | -                  | 0.324   |                       |         |
| Ampullary                  | 7                   | 20.0               |         |                       |         |
| Tumor size                 |                     |                     |         |                       |         |
| ≤3 cm                      | 14                  | -                  | 0.036   | 1.942[0.606,6.223]    | 0.264   |
| >3 cm                      | 18                  | 12.0               |         |                       |         |
| T                          |                     |                     |         |                       |         |
| T1/T2                      | 7                   | -                  | 0.030   | 3.611[0.335,38.888]   | 0.290   |
| T3/T4                      | 25                  | 22.0               |         |                       |         |
| Lymph node metastasis      |                     |                     |         |                       |         |
| No                         | 8                   | -                  | 0.013   | 8.380[1.096,64.094]   | 0.041   |
| Yes                        | 24                  | 20.0               |         |                       |         |
| TNM stage                  |                     |                     |         |                       |         |
| I/II                       | 10                  | -                  | 0.015   | 0.797[0.082,7.792]    | 0.846   |
| III/IV                     | 22                  | 20.0               |         |                       |         |
| Ki67 (%)                   |                     |                     |         |                       |         |
| ≤20                        | 3                   | 22.0               | 0.638   |                       |         |
| >20                        | 29                  | 26.0               |         |                       |         |
| Cell type of NEC           |                     |                     |         |                       |         |
| Large cell                 | 11                  | -                  | 0.612   |                       |         |
|                                |      |   |
|--------------------------------|------|---|
| **Non-large cell**             | 21   | 25.0 |
| **Lymphatic invasion**         |      |     |
| Presence                       | 27   | 22.0 |
| Presence                       | 5    | -    |
| **Vascular invasion**          |      |     |
| Presence                       | 23   | 20.0 |
| Presence                       | 9    | -    |
| **Perineural invasion**        |      |     |
| Presence                       | 22   | 22.0 |
| Presence                       | 10   | -    |
| **Grade of adenocarcinoma**    |      |     |
| Well/Moderate differentiation  | 20   | -    |
| Poor/Signet ring cell/Mucin    | 12   | 9.0  |
| Syn                            |      |     |
| (+)                            | 31   | 25.0 |
| (+)                            | 1    | -    |
| CgA                            |      |     |
| (+)                            | 26   | 26.0 |
| (+)                            | 6    | 25.0 |
| CD56                           |      |     |
| (+)                            | 18   | -    |
| (+)                            | 14   | 9.0  |
| PCK                            |      |     |
| (+)                            | 18   | 26.0 |
| (+)                            | 14   | 22.0 |
| EMA                            |      |     |
| (+)                            | 11   | 25.0 |
| (+)                            | 21   | 26.0 |
| CK7  |   |   |   |
|------|---|---|---|
| (+)  | 8 | 20.0 | 0.515 |
| (-)  | 24 | 26.0 |

| Chemotherapy |   |   |   |
|--------------|---|---|---|
| Yes          | 11 | 26.0 | 0.71 |
| No           | 21 | 25.0 |

**Table 3** Univariate and multivariate analyses of prognostic factors that influence overall survival of MANEC in gastric and ampullary. MANEC Mixed adenoneuroendocrine carcinomas, *AJCC TNM staging system of tumors (7th edition, 2010)*
| Variables                      | Univariate analysis | Multivariate analysis |
|-------------------------------|---------------------|-----------------------|
|                               | No. of patients (%) | MOS (months) | P value | Hazard ratio (95% CI) | P value |
| Age (years)                   |                     |             |         |                      |         |
| <60                           | 16                  | 24.0        | 0.297   |                      |         |
| ≥60                           | 16                  | 42.0        |         |                      |         |
| Sex                           |                     |             |         |                      |         |
| male                          | 26                  | 28.0        | 0.539   |                      |         |
| female                        | 6                   | 24.0        |         |                      |         |
| Tumor location                |                     |             |         |                      |         |
| Stomach                       | 25                  | 25.0        | 0.644   |                      |         |
| Nonstomach                    | 7                   | 28.0        |         |                      |         |
| Tumor size                    |                     |             |         |                      |         |
| ≤3 cm                         | 14                  | -           | 0.001   | 3.006[0.992,9.107]   | 0.052   |
| >3 cm                         | 18                  | 15.0        |         |                      |         |
| T                             |                     |             |         |                      |         |
| T1–T2                         | 7                   | -           | 0.006   | 6.089[0.549,67.571]  | 0.141   |
| T3–T4                         | 25                  | 24.0        |         |                      |         |
| Lymph node metastasis         |                     |             |         |                      |         |
| No                            | 8                   | -           | 0.004   | 10.617[1.409,79.997] | 0.022   |
| Yes                           | 24                  | 18.0        |         |                      |         |
| TNM stage                     |                     |             |         |                      |         |
| I/II                          | 10                  | -           | 0.004   | 6.444[1.477,28.121]  | 0.013   |
| III/IV                        | 22                  | 18.0        |         |                      |         |
| Grade of adenocarcinoma       |                     |             |         |                      |         |
| Well/Moderate differentiation | 20                  | 42.0        | 0.003   | 3.876[1.451,10.357]  | 0.007   |
| Poor/signet ring cell/mucin   | 12                  | 12.0        |         |                      |         |
| Ki 67(%)                      |                     |             |         |                      |         |
|                    | Count | Mean | Median | P value | 95% CI | 0.05 | 97.5%
|--------------------|-------|------|--------|---------|--------|------|--------
| Age                |       |      |        |         |        |      |        |
| <20                | 3     | 24.0 | 24.0   | 0.919   |        |      |        |
| >20                | 29    | 28.0 |        |         |        |      |        |
| Cell type of NEC   |       |      |        |         |        |      |        |
| Large cell         | 11    | 25.0 | 25.0   | 0.956   |        |      |        |
| Non-large cell     | 21    | 28.0 |        |         |        |      |        |
| Lymphatic invasion |       |      |        |         |        |      |        |
| Presence           | 27    | 24.0 | 24.0   | 0.018   | -      | 0.972|        |
| Absence            | 5     | -    | -      |         |        |      |        |
| Vascular invasion  |       |      |        |         |        |      |        |
| Presence           | 18    | 24.0 | 24.0   | 0.006   | 5.855[1.719,19.940] | 0.005|        |
| Absence            | 14    | -    | -      |         |        |      |        |
| Perineural invasion|       |      |        |         |        |      |        |
| Presence           | 20    | 24.0 | 24.0   | 0.450   |        |      |        |
| Absence            | 12    | 30.0 |        |         |        |      |        |
| Syn                | (+)   | 31   | 25.0   | 0.669   |        |      |        |
| (-)                | 1     | 28.0 |        |         |        |      |        |
| CgA                | (+)   | 26   | 25.0   | 0.496   |        |      |        |
| (-)                | 6     | 28.0 |        |         |        |      |        |
| CD56               | (+)   | 14   | 30.0   | 0.006   | 0.265[0.100,0.705] | 0.008|        |
| (-)                | 18    | 12.0 |        |         |        |      |        |
| PCK                | (+)   | 18   | 25.0   | 0.736   |        |      |        |
| (-)                | 14    | 28.0 |        |         |        |      |        |
| EMA                | (+)   | 11   | 25.0   | 0.657   |        |      |        |
| (-)                | 21    | 28.0 |        |         |        |      |        |
| CK7   |   |   |   |
|-------|---|---|---|
| (+)   | 8 | 24.0 | 0.915 |
| (-)   | 24 | 25.0 |

**Chemotherapy**

|     |   |   |   |
|-----|---|---|---|
| Yes | 11 | 24.0 | 0.758 |
| No  | 21 | 28.0 |

**Figures**

Figure 1

Immunohistochemistry for chromogranin A, Original magnification, ×200, B. Immunohistochemistry for Syn, Original magnification, ×200, C. Hematoxylin and eosin (H&E) staining, Original magnification, ×100.
Figure 2

Comparison of recurrence between patients with and without lymphatic invasion (P=0.027);
Figure 3

Comparison of recurrence between patients with and without vascular invasion (P = 0.006);
Figure 4

Comparison of overall survival between patients with high/moderate differentiation and poor/signet ring cell/mucin differentiation (P = 0.003);
Figure 5

Comparison of overall survival between patients with CD56 (+) and CD56(-) (P = 0.006).